Arrowhead Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Arrowhead Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ARWR

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. 

CEO
Christopher Richard Anzalone
CEOChristopher Richard Anzalone
Employees
711
Employees711
Headquarters
Pasadena, California
HeadquartersPasadena, California
Founded
1989
Founded1989
Employees
711
Employees711

ARWR Key Statistics

Market cap
12.24B
Market cap12.24B
Price-Earnings ratio
-38.26
Price-Earnings ratio-38.26
Dividend yield
Dividend yield
Average volume
1.69M
Average volume1.69M
High today
$88.67
High today$88.67
Low today
$85.70
Low today$85.70
Open price
$87.93
Open price$87.93
Volume
346.06K
Volume346.06K
52 Week high
$95.49
52 Week high$95.49
52 Week low
$15.01
52 Week low$15.01

Stock Snapshot

With a market cap of 12.24B, Arrowhead Pharmaceuticals(ARWR) trades at $86.86. The stock has a price-to-earnings ratio of -38.26.

On 2026-08-07, Arrowhead Pharmaceuticals(ARWR) stock traded between a low of $85.70 and a high of $88.67. Shares are currently priced at $86.86, which is +1.4% above the low and -2.0% below the high.

The Arrowhead Pharmaceuticals(ARWR)'s current trading volume is 346.06K, compared to an average daily volume of 1.69M.

In the last year, Arrowhead Pharmaceuticals(ARWR) shares hit a 52-week high of $95.49 and a 52-week low of $15.01.

In the last year, Arrowhead Pharmaceuticals(ARWR) shares hit a 52-week high of $95.49 and a 52-week low of $15.01.

ARWR News

Simply Wall St 2d
Arrowhead Pharmaceuticals Stock Retreats As Losses Deepen Behind Phase III Progress - simplywall.st

...

Arrowhead Pharmaceuticals Stock Retreats As Losses Deepen Behind Phase III Progress - simplywall.st
TipRanks 2d
Arrowhead: Buy Rating Reiterated as Redemplo Momentum Builds and Pipeline Catalysts Support Unchanged $120 Price Target

Arrowhead Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Ulz from Morgan Stanley reiterated a Buy...

Simply Wall St 5d
The Bull Case For Arrowhead Pharmaceuticals Could Change Following Plozasiran’s Phase 3 Success And Zodasiran Milestone

Arrowhead Pharmaceuticals recently reported that its Phase 3 SHASTA-3 and SHASTA-4 trials of plozasiran in severe hypertriglyceridemia met all primary and secon...

The Bull Case For Arrowhead Pharmaceuticals Could Change Following Plozasiran’s Phase 3 Success And Zodasiran Milestone

Analyst ratings

93%

of 14 ratings
Buy
92.9%
Hold
7.1%
Sell
0%

People also own

Based on the portfolios of people who own ARWR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.